RESUMEN
Objective To summarize the effect and safety of paclitaxel drug-coated balloon in the treatment of patients with coronary in-stent restenosis.Methods From August 2015 to July 2018,30 patients with in-stent restenosis in Jinqiu Hospital of Liaoning Province were selected and they had undertook the percutaneous transluminal coronary angioplasty(PTCA) with paclitaxel drug-coated balloon under intravascular ultrasound-guided.Results Intravascular ultrasound was done after PTCA with ordinary balloon before the paclitaxel drug - coated balloon angioplasty.The drug-coated balloon expansion continued to 30s-60s[(43 ± 11)s] in all in-stent restenosis,and the success rate of immediate intervention operation was 100%.The lesion degree of stenosis and lesions minimum diameter at postoperation and preoperation had statistically significant differences[(10.67 ± 5.53)% vs.(79.67 ± 9.28)% ,t= -33.797,P<0.01;(2.80 ± 0.44)mm vs.(0.64 ± 0.31)mm,t=22.039,P<0.01].There was one 89-year-old patient died because of respiratory failure from pneumonia,and two patients with angina pectoris after operation got relieve after one week drug treatment. There were no other adverse cardiovascular events during the duration of hospital stay after the intervention operation.Conclusion Paclitaxel drug-coated balloon is effective and safe in the treatment of patients with coronary in - stent restenosis lesions. It is one new method named " the intervention without once again permanent implant " that the paclitaxel drug - coated balloon expands under intravascular ultrasound-guided,but the long-term effect is uncertain yet.